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Abstract
Chromosome rearrangements can form when incorrect ends are matched during end joining (EJ) repair of multiple
chromosomal double-strand breaks (DSBs). We tested whether the ATM kinase limits chromosome rearrangements via
suppressing incorrect end utilization during EJ repair of multiple DSBs. For this, we developed a system for monitoring EJ of
two tandem DSBs that can be repaired using correct ends (Proximal-EJ) or incorrect ends (Distal-EJ, which causes loss of the
DNA between the DSBs). In this system, two DSBs are induced in a chromosomal reporter by the meganuclease I-SceI. These
DSBs are processed into non-cohesive ends by the exonuclease Trex2, which leads to the formation of I-SceI–resistant EJ
products during both Proximal-EJ and Distal-EJ. Using this method, we find that genetic or chemical disruption of ATM
causes a substantial increase in Distal-EJ, but not Proximal-EJ. We also find that the increase in Distal-EJ caused by ATM
disruption is dependent on classical non-homologous end joining (c-NHEJ) factors, specifically DNA-PKcs, Xrcc4, and XLF.
We present evidence that Nbs1-deficiency also causes elevated Distal-EJ, but not Proximal-EJ, to a similar degree as ATM-
deficiency. In addition, to evaluate the roles of these factors on end processing, we examined Distal-EJ repair junctions. We
found that ATM and Xrcc4 limit the length of deletions, whereas Nbs1 and DNA-PKcs promote short deletions. Thus, the
regulation of end processing appears distinct from that of end utilization. In summary, we suggest that ATM is important to
limit incorrect end utilization during c-NHEJ.
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Introduction
Recent sequencing of cancer genomes has revealed a prevalence
of chromosome rearrangements, including interchromosomal
translocations and intrachromosomal rearrangements [1]. These
rearrangements could arise from end joining (EJ) of incorrect ends
of multiple chromosomal double-strand breaks (DSBs). Such EJ
could be performed by classical non-homologous end joining (c-
NHEJ) factors that mediate V(D)J Recombination (e.g. Ku70/
Ku80, XLF, DNA-PKcs, and Xrcc4/Lig4), or by Alternative-EJ
(alt-EJ) pathways that are independent of these factors [2,3]. We
suggest that identifying the mechanisms that are important for the
fidelity of end utilization during c-NHEJ and/or alt-EJ will
provide insight into maintenance of chromosome stability and
tumor suppression.
Factors that reduce incorrect end utilization during EJ are likely
to be important for suppressing chromosome rearrangements.
Mutations in the ATM kinase, found in patients with the genetic
disorder Ataxia-Telangiectasia (A-T), cause elevated levels of
chromosomal abnormalities, along with a predisposition for cancer
[4]. Part of the role of ATM in suppressing chromosomal
abnormalities is likely related to its key function during the DNA
Damage Response (DDR). Without the DDR, cells fail to activate
cell cycle checkpoints following DNA damage, and are more likely
to undergo DNA replication and/or mitosis with broken chromo-
somes, which could lead to rearrangements [5]. Also important for
the DDR is Nbs1, which is a member of the Mre11-complex
(Mre11-Rad50-Nbs1) and is important for ATM activation [6,7].
Patients with mutations in the Nbs1 gene (Nijmegen Breakage
Syndrome), like A-T patients, show cancer predisposition associated
with elevated chromosomal abnormalities [8].
ATM and Nbs1 localize to sites of DSBs, and are important for
theirrepair [6,9]. Both ATM and Nbs1 are important for cell survival
following ionizing radiation (IR)-induced DSBs [4,8], and promote
homologous recombination [10]. Also consistent with a roleinrepair,
a subset of IR-induced DSBs persist in ATM-deficient cells [11].
Persistent breaks have also been observed in ATM-deficient
lymphocytes during V(D)J recombination and class switch recombi-
nation (CSR) [12–15]. ATM and Nbs1 affect the repair fidelity of
certain V(D)J recombination substrates, in which the Rag1/2
nuclease forms two types of DSB ends: hairpin coding-ends and
blunt signal-ends [13,16,17]. Correct end utilization in this context
involves pairing coding-coding and signal-signal ends during NHEJ.
When Rag1/2 cleavage sites are placed in an inverted orientation,
both ATM and Nbs1 have been shown to suppress hybrid signal-
coding EJ products [13,16–18]. Thus, these factors are important for
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ATM-deficient lymphocytes show elevated chromosome rearrange-
ments resulting from V(D)J recombination [19,20]. ATM and Nbs1
also promote efficient CSR and suppress translocations between IgH
and c-myc during this process [9,12,21–25]. Similarly, the ATM
orthologue in yeast (TEL1) is important to suppress translocations in
favor of intrachromosomal EJ [26].
Thus, we considered the possibility that ATM and/or Nbs1 play a
role in correct end utilization during EJ repair of multiple
chromosomal DSBs in mammalian cells, outside of the programmed
rearrangements during lymphocyte development. For this, we
monitored EJ products following the induction of two tandem DSBs,
which can be repaired using either correct ends (Proximal-EJ) or
incorrect ends (Distal-EJ). We find that disruption of ATM or Nbs1
causes elevated Distal-EJ, but not Proximal-EJ. Furthermore, the
elevation of Distal-EJ caused by ATM-disruption is dependent on the
c-NHEJ factors DNA-PKcs, Xrcc4, and XLF. In addition, to
examine the role of these factors on end processing, we analyzed
Distal-EJ repair junctions. We find that ATM and Xrcc4 limit
extensive deletions during EJ, whereas Nbs1 and DNA-PKcs
promote short deletions. Thus, the role of individual factors during
end processing does not directly correlate with their roles during end
utilization. In summary, we suggest that ATM is important to limit
incorrect end utilization during repair by c-NHEJ.
Results
Reporter for Distal-EJ versus Proximal-EJ of two tandem
DSBs
We investigated incorrect and correct end utilization during EJ
repair of two tandem DSBs. In this context, incorrect end
utilization involves the joining of distal DSB ends (Distal-EJ), as
this repair event leads to an intrachromosomal deletion between
the two DSBs. In contrast, correct end utilization maintains
proximal ends during repair (Proximal-EJ). We developed a
method to measure Proximal-EJ and Distal-EJ repair of two
tandem chromosome breaks generated by the meganuclease I-
SceI, using the reporter EJ5-GFP (Figure 1) [27,28]. In this
reporter, a promoter is separated from the rest of a GFP
expression cassette by 1.7 kb (puro cassette) that is flanked by two
tandem I-SceI sites. Following I-SceI expression, Distal-EJ places
the promoter adjacent to the rest of the GFP-expression cassette,
such that Distal-EJ can be quantified as the percentage of GFP+
cells [27,28].
Proximal-EJ is difficult to measure with I-SceI expression alone,
since EJ that restores the I-SceI site cannot be differentiated from
the uncut reporter [27]. Thus, we adapted this reporter system to
enable the quantification of I-SceI-resistant Proximal-EJ products
by co-expressing I-SceI with a non-processive 39 exonuclease
(Trex2). As described previously, expression of Trex2 appears to
cause partial degradation of the 4 nt. 39 cohesive ends generated
by I-SceI, such that co-expression of I-SceI with Trex2 leads to a
high level of I-SceI-resistant Proximal-EJ products [27]. Thus,
Proximal-EJ can be quantified by loss of the I-SceI site through
PCR amplification across the 39 I-SceI site, and subsequent I-SceI
digestion analysis (Figure 1, primers p1, p2). In this assay we
determine the percentage of I-SceI-resistant events by quantifying
the relative intensity of the I-SceI-resistant and I-SceI-sensitive
products within the same sample. This approach has been
described previously for other I-SceI assays [29], and confirmed
here to be quantitative within at least two-fold (Figure S1A).
Figure 1. Measuring end utilization during EJ repair of two
tandem DSBs. Shown is the EJ5-GFP reporter, which contains a GFP
coding sequence that is separated from its promoter by a puromycin
resistance gene (puro) that is flanked by two tandem I-SceI sites. We
express I-SceI to induce two DSBs with four nt. 39 overhangs, and co-
express Trex2 to cause partial degradation of these overhangs, leading
to I-SceI-resistant EJ products. Shown on the left is the Distal-EJ repair
product that causes the deletion of puro and restoration of the GFP+
cassette, which can be measured by FACS analysis. Also depicted are
two primers (p3, p2) for analysis of Distal-EJ repair junctions. Shown on
the right is the Proximal-EJ product, which is quantified by I-SceI
digestion analysis of an amplification product that spans the 39 I-SceI
site (primers p1, p2). This approach enables quantification of two
different I-SceI-resistant EJ products from the same sample: Distal-EJ
(%GFP+ cells) and Proximal-EJ (% I-SceI-resistant product). Proximal-EJ is




When a chromosome is fragmented by multiple double-
strand breaks (DSBs), each set of DSB ends needs to be
matched correctly during repair to avoid chromosomal
rearrangements. Considering the case of two tandem
DSBs, if the ends of different breaks (incorrect ends) are
used for repair, loss of the intervening DNA can occur.
Alternatively, when the ends of a single DSB (correct ends)
are used for repair, the original order of the chromosome is
restored. Deficiencies in the factors ATM and Nbs1, as seen
in patients with Ataxia Telangiectasia and Nijmegen
Breakage Syndrome, respectively, have been associated
with elevated chromosome rearrangements and cancer
predisposition. Hence, we examined the possibility that
these factors may be important for the usage of correct
ends during repair of multiple DSBs. For this, we
developed a reporter system to examine end usage during
repair of two tandem DSBs in mammalian chromosomes
and found that disruption of ATM or Nbs1 leads to
elevated usage of incorrect ends. Furthermore, we found
that the role of ATM during end usage depends on a repair
pathway called classical non-homologous end joining (c-
NHEJ). We suggest that ATM suppresses genome rear-
rangements via limiting incorrect end utilization during c-
NHEJ.
ATM and End Utilization
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substantially more efficient than Distal-EJ [27]. To confirm this
finding, we co-expressed I-SceI with Trex2 in a WT mouse ES cell
line with a chromosomally integrated copy of EJ5-GFP [28], and
analyzed the EJ repair products, as described above (Figure 1).
From these experiments, we observed low levels of Distal-EJ (0.2%
GFP+ cells, Figure 2A), and much higher levels of Proximal-EJ
(13% I-SceI-resistant p1,p2 amplification products, Figure 2B). In
contrast, following transfection of I-SceI without Trex2, we found
no detectable I-SceI-resistant Proximal-EJ products (Figure 2B).
These results indicate that Proximal-EJ predominates following
Trex2 and I-SceI co-expression, such that this experimental
approach may uncover factors important for correct end
utilization that are otherwise masked from experiments using I-
SceI expression alone.
Importantly, the Distal-EJ products resulting from co-expression
of I-SceI and Trex2 are also completely I-SceI-resistant [27]. We
have confirmed this notion here, using GFP+ sorted samples from
the aforementioned transfection experiment (Figure 2C, Figure
S1B). Therefore, this method can be used to measure the
frequency of two different I-SceI-resistant products (Distal-EJ
and Proximal-EJ) from a single sample (Figure 1).
ATM-disruption causes elevated Distal-EJ but not
Proximal-EJ
We considered the possibility that ATM may affect end
utilization during EJ, as this factor is important for chromosome
stability [4]. To test this hypothesis, EJ5-GFP was chromosomally
integrated into ATM
2/2 mouse ES cells [30], and analyzed in
parallel with the WT ES cell line described above. Furthermore,
Figure 2. ATM suppresses Distal End Utilization. EJ5-GFP was integrated into wild type (WT) and ATM
2/2 mouse ES cells. These lines were co-
transfected with expression plasmids for I-SceI and Trex2, and treated with ATMi or DMSO (vehicle). Subsequently, frequencies of Distal-EJ and
Proximal-EJ were determined as described in Figure 1. A. ATM suppresses Distal-EJ. Shown (left) are two representative FACS profiles for WT mouse ES
cells transfected and treated with DMSO or ATMi, as described above. Also shown (right) are the mean GFP+ frequencies (Distal-EJ) for WT and ATM
2/2
cells transfected and treated with DMSO or ATMi, as described above (N=6, error bars denote s.d.). (*) statistical difference between DMSO and ATMi
treatments of the same cell line (p,0.0001), ({) statistical difference between WT and mutant ES cell lines under the same treatment conditions
(p,0.0001). B. Proximal-EJ is modestly reduced by ATMi treatment of WT cells, but is the same for WT and ATM
2/2 cells. Formation of an I-SceI-resistant
EJ product at the 39 I-SceI site (Proximal-EJ) was determined by amplification (primers p1, p2) of genomic DNA samples from the transfection
experiments shown in A, followed by I-SceI digestion analysis. Shown (left) are representative samples of uncut (U) and I-SceI-digested (S) products
following co-transfection of expression vectors for I-SceI and Trex2 (S+Trex2), or co-transfection of an expression vector for I-SceI with empty vector
(S+EV). Alsoshown(right)arethe meanProximal-EJfrequenciesfromtheidentical transfection samplesshown inA (N=6,errorbars denotes.d.).(*) asin
A (p=0.0007). C. Co-expression of I-SceI and Trex2 leads to Distal-EJ products that are I-SceI-resistant. The Distal-EJ junctions were amplified from
genomic DNA of sorted GFP+ cells (primers p2, p3) from a representative of each transfection described in A. Shown are uncut (U) and I-SceI-digested
(S) amplification products from these samples. D. Disruption of ATM leads to elevated Distal End Utilization. Distal End Utilization was calculated by
dividing Distal-EJ (% GFP+ cells) by Proximal-EJ (% I-SceI resistant p1, p2 product) for individual samples of the transfections described in A. Mean values
are depicted relative to the mean Distal End Utilization value for WT DMSO-treated cells (N=6, error bars denote s.d.). (*) as in A (p,0.0001). ({)a si nA
(p#0.0035).
doi:10.1371/journal.pgen.1001194.g002
ATM and End Utilization
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either a highly-specific ATM kinase inhibitor (ATMi) [31] or
vehicle (DMSO). Subsequently, the percentage of GFP+ cells
(Distal-EJ) was measured by FACS analysis. From these
experiments, we found that ATMi treatment of WT cells caused
an increase in Distal-EJ, as compared to DMSO treated cells (3.4-
fold, p,0.0001, Figure 2A). Similarly, ATM
2/2 cells exhibited
higher levels of Distal-EJ as compared to WT cells (7.4-fold,
p,0.0001, Figure 2A). Finally, treatment of the ATM
2/2 cells
with ATMi had no effect on Distal-EJ, which is consistent with the
high-specificity of ATMi [31]. These data indicate that ATM
kinase activity is important for the suppression of Distal-EJ.
To measure Proximal-EJ, we isolated genomic DNA from the
same samples used in the FACS analysis, and determined the
percentage of I-SceI-resistant amplification products, as described
above (Figure 1, primers p1, p2). For both WT and ATM-deficient
cells, we found that co-expression of I-SceI and Trex2 results in a
significant level of I-SceI-resistant Proximal-EJ products, which
are not detectable from expression of I-SceI alone (S+Trex2 versus
S+EV, respectively, Figure 2B, Figure S1C). Regarding frequen-
cies, we found that WT and ATM
2/2 cells exhibited equivalent
levels of Proximal-EJ (Figure 2B). ATMi treatment caused a
modest reduction in Proximal-EJ in WT cells (Figure 2B, 1.5-fold,
p=0.0007), but not in ATM
2/2 cells. Thus, loss of ATM kinase
activity, but not complete disruption of ATM, appears to modestly
reduce Proximal-EJ. Importantly, neither ATMi nor genetic
disruption of ATM caused an increase in Proximal-EJ.
We then directly compared Distal-EJ and Proximal-EJ values to
determine the relative frequency of incorrect end utilization (Distal
End Utilization). First, we confirmed that the Distal-EJ products
(GFP+) formed following I-SceI and Trex2 co-expression were I-
SceI-resistant for all cell types. We sorted GFP+ cells, isolated
genomic DNA, amplified the Distal-EJ products (Figure 1, primers
p2, p3), and performed I-SceI digestion analysis. We found that
Distal-EJ products were completely I-SceI-resistant for both WT
and ATM-deficient cells following I-SceI and Trex2 co-expression,
unlike Distal-EJ products resulting from transfection with I-SceI
alone (Figure 2C, Figure S1B). We then quantified Distal End
Utilization by calculating the ratio of Distal-EJ versus Proximal-EJ
for individual samples. From this analysis, we found that ATMi-
treatment of WT cells led to a substantial increase in Distal End
Utilization in comparison to DMSO treated cells (Figure 2D, 5.3-
fold, p,0.0001). Similarly, ATM
2/2 cells exhibited a striking
increase in Distal End Utilization, in comparison to WT cells
(Figure 2D,8.7-fold,p,0.0001).Last,ATMi-treatmentofATM
2/2
cells did not affect Distal End Utilization.
In the above experiments, ATM appears to suppress Distal-EJ
without promoting Proximal-EJ to a similar degree. However, in
all conditions, Proximal-EJ is predominant (e.g. 13% for WT,
11.7% for ATM
2/2) over the minor Distal-EJ product (e.g. 0.2%
for WT, 1.6% for ATM
2/2). Thus, Distal-EJ is relatively
infrequent, as compared to Proximal-EJ. Accordingly, the fold-
increase in Distal-EJ caused by ATM-disruption would not
necessarily be matched by a similar fold-decrease in Proximal-
EJ. Considering one other detail of these experiments, we note that
determining the effect of ATMi on Distal End Utilization after 6
days of culturing post-transfection was not statistically different
from the 3 days protocol described in Figure 2 (Figure S1D). This
finding indicates that 3 days is a reasonable end-point for these
experiments.
We next considered the possibility that ATM might inhibit the
formation of both I-SceI-induced DSBs, which would limit Distal-
EJ. For this, we used clonal analysis to determine the frequency of
I-SceI-resistant Proximal-EJ products at both tandem I-SceI sites.
Specifically, we expressed I-SceI and Trex2 in WT ES cells treated
with ATMi or DMSO. Following the usual 3 days of culturing, we
plated transfected cells at low density to isolate single clones. For
individual clones, we determined whether the 59 and/or 39 I-SceI
recognition sites had been lost, by performing PCR amplification
and I-SceI digestion analysis. From this experiment, we found that
clones with loss of either the 59 or 39 I-SceI site frequently lost the
second site (Figure S2A; WT DMSO treated cells: 19 clones lost
both 59 and 39 sites, 18 clones lost only one of the sites). Thus,
cutting at two tandem I-SceI sites, followed by EJ that leads to I-
SceI-resistant products at both sites, appears efficient in WT cells.
Furthermore, ATMi treatment did not cause an increase in clones
that lost both I-SceI sites (Figure S2A; WT ATMi treated cells: 9
clones lost both 59 and 39 sites, 25 clones lost only one of the sites).
These results indicate that ATM does not suppress the formation
of tandem I-SceI-induced DSBs. However, we note that these
experiments do not address potential effects of ATM on the
probability that both DSBs persist simultaneously (see break
persistence model in Discussion).
We also performed the ATMi analysis in a distinct cell type: a
transformed human embryonic kidney cell line (HEK293, Figure
S2B) that contains a chromosomally integrated EJ5-GFP reporter
[28]. Using this HEK293-EJ5-GFP cell line for the same
transfection experiment described for ES cells, we found that
ATMi treatment caused elevated levels of Distal-EJ (2.1-fold,
p,0.0001), but did not affect Proximal-EJ, leading to an increase
in Distal End Utilization (Figure S2B, 2.2-fold, p,0.0001).
Combined, these findings indicate that ATM is important for
limiting Distal End Utilization during EJ repair of multiple DSBs
in both mouse ES and human HEK293 cells.
ATM limits Distal-EJ only in c-NHEJ proficient cells
We next tested whether the increase in Distal-EJ that is caused
by ATM-disruption involves c-NHEJ factors, specifically DNA-
PKcs, Xrcc4, and/or XLF. DNA-PKcs is recruited to DSBs by the
Ku70/Ku80 heterodimer, and can stabilize the two ends of a DSB
prior to ligation by the Xrcc4/Lig4 complex, which is promoted
by XLF [2]. We integrated EJ5-GFP into DNA-PKcs
2/2 [32],
Xrcc4
2/2 [33], and XLF
2/2 [34] ES cells, and analyzed EJ
efficiency in these cell lines following expression of I-SceI and
Trex2, along with ATMi or DMSO treatment, as described above
for WT cells. From these experiments (Figure 3A), we found that
ATMi treatment did not affect Distal-EJ in DNA-PKcs
2/2 and
XLF
2/2 cells, and caused a decrease in Distal-EJ in Xrcc4
2/2 cells
(1.9-fold, p,0.0001), all of which are distinct from the 3.4-fold
increase observed in WT cells. Importantly, these results indicate
that DNA-PKcs, Xrcc4, and XLF are essential for the increase in
Distal-EJ caused by ATM-disruption.
Regarding overall frequencies of EJ in ATM-proficient cells, we




2/2 cells. For instance, we found that I-SceI-
resistant Proximal-EJ products were below the level of detection
for both the DNA-PKcs
2/2 and XLF
2/2 cells (,2%, Figure 3B),
similar to previous findings in Xrcc4
2/2 cells [27] that we have
repeated here (Figure 3B). These results indicate that DNA-PKcs,
Xrcc4, and XLF are essential for significant levels of Proximal-EJ
of DSB ends processed by Trex2. Consistent with these results,
DNA-PKcs, Xrcc4/Ligase IV, and XLF were previously shown to
promote NHEJ of non-cohesive DSB ends in vitro [35]. Regarding
Distal-EJ frequencies compared to WT cells, DNA-PKcs
2/2 and
Xrcc4
2/2 cells showed a reduction (1.6-fold, p,0.0001, and 1.3-
fold, p=0.0041, respectively, Figure 3A), whereas XLF
2/2 cells
exhibited an increase in Distal-EJ (1.8-fold, p=0.0014, Figure 3A).
Unfortunately, since Proximal-EJ is below the limit of detection in
ATM and End Utilization
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Utilization for these cell lines. Nevertheless, Proximal-EJ is
substantially reduced in these cells (,2%) compared to WT cells
(13%), whereas Distal-EJ levels in these cells are within 2-fold of
WT cells. These results indicate that DNA-PKcs, Xrcc4, and XLF
are important for correct end utilization.
We then sought to determine whether the EJ events measured
with EJ5-GFP may be mechanistically distinct from c-NHEJ
during V(D)J recombination. For this, we examined the c-NHEJ
factor Artemis: a nuclease that is important for hairpin opening
during V(D)J recombination [2]. We integrated the EJ5-GFP
reporter into Artemis
2/2 ES cells [36], and performed the
transfection analysis described above. In contrast to the above c-
NHEJ factors, Artemis
2/2 cells showed no clear distinction from
WT cells on the frequencies of Distal-EJ, Proximal-EJ, or Distal
End Utilization, nor on the effect of ATMi treatment on these EJ
events (Figure 3). These results indicate that Artemis is not
involved in these EJ processes, which provides a contrast to the
findings with DNA-PKcs, Xrcc4, and XLF. These findings also
confirm the notion that repair of the EJ events measured here
show mechanistic distinctions from the hybrid coding-signal joints
of V(D)J recombination substrates, which are also elevated in
ATM-deficient cells, yet require Artemis [2,18,36].
Nbs1 limits Distal-EJ but not Proximal-EJ, similar to ATM
As Nbs1 is important for activation of ATM following DSBs
[6,7], we considered that this factor might also affect end
utilization. To test this hypothesis, we used an Nbs1-hypomorphic
mouse ES cell line (Nbs1
n/h), in which both alleles of the Nbs1 gene
are targeted [37], causing a 5-fold decrease in the level of Nbs1
protein [27]. The Nbs1
n/h cell line containing EJ5-GFP was
described previously, and shown to exhibit an elevated level of
Figure 3. The elevation in Distal-EJ caused by ATMi is dependent on DNA-PKcs, Xrcc4, and XLF, but not Artemis. A. Shown are mean




2/2 mouse ES cell lines, each with an integrated EJ5-GFP reporter, which
were transfected and treated with DMSO or ATMi, as described in Figure 2 (N=6, error bars denote s.d.). (*) statistical difference between DMSO
versus ATMi treatments of the same cell line (p,0.0001), ({) statistical difference between WT and mutant ES cell lines of the same treatment
(p#0.0014). B. Proximal-EJ requires DNA-PKcs, Xrcc4, and XLF, but not Artemis. Shown are representative samples of uncut (U) and I-SceI-digested (S)
p1, p2 amplification products from representative transfections described in A. C. The effect of ATMi on EJ is not distinct between WT and Artemis
2/2
cells. Shown (left) are the mean frequencies of Proximal-EJ for the WT and Artemis
2/2 transfection experiments described in A (N=6, error bars
denote s.d.). (*) as in A, p,0.0001 for WT, p=0.0461 for Artemis
2/2. Shown (right) are mean Distal End Utilization values of individual samples relative
to DMSO-treated WT cells (N=6, error bars denote s.d.). (*) as in A (p,0.0001).
doi:10.1371/journal.pgen.1001194.g003
ATM and End Utilization
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Nbs1 on the relative efficiency of Proximal-EJ and Distal-EJ, as
well as the effect of ATMi treatment on these EJ events, we
performed the aforementioned I-SceI/Trex2 experiment using the
Nbs1
n/h-EJ5-GFP cell line. We found that Nbs1
n/h cells exhibited a
substantial increase in Distal-EJ repair relative to WT cells (5.1-
fold, p,0.0001, Figure 4A). ATMi treatment of the Nbs1
n/h cells
caused a modest increase in Distal-EJ (1.4-fold, p=0.0053,
Figure 4A). Proximal-EJ was equally efficient in WT and Nbs1
n/h
cells, and ATMi treatment of the Nbs1
n/h cells casued a slight
reduction in the frequency of Proximal-EJ (1.3-fold, p=0.0156,
Figure 4B). Lastly, Distal End Utilization in Nbs1
n/h cells was
higher than in WT cells (4.9-fold, p,0.0001, Figure 4C), and was
enhanced by ATMi treatment (1.8-fold, p=0.0011, Figure 4C).
Notably, the effect of ATMi on Distal End Utilization in Nbs1
n/h
cells (1.8-fold, Figure 4C) is substantially reduced as compared to
the effect in WT cells (5.3-fold, Figure 2D, Figure 4C). In
summary, these data indicate that Nbs1 is important to limit Distal
End Utilization to a similar degree as ATM.
The role of individual factors during Distal-EJ is not
predictive of their effect on end processing
Apart from suppressing Distal End Utilization, we considered
whether ATM and/or Nbs1 might also affect the degree of end
processing during EJ. For this, we cloned Distal-EJ amplification
products from GFP+ sorted cells following I-SceI and Trex2 co-
expression of WT (DMSO and ATMi treated), ATM
2/2, and
Nbs1
n/h cells (DMSO and ATMi treated), (p3, p2 products shown
in Figure 2C, Figure S1B). For each condition, 30 independent
clones were sequenced to determine the Distal-EJ repair junctions.
As compared to an I-SceI+ Distal-EJ product, we classified the
sequences into five groups: +1 insertion, 1 to 5 nt. deletions, 6 to
9 nt. deletions, 10 to 19 nt. deletions, and $20 nt. deletions
(Figure 5 and Table S1). For WT cells, we found that Distal-EJ
products showed mostly deletions of the I-SceI overhang region
(17/30 with 1 to 5 nt. deletions), and the remaining clones showed
only slightly larger deletions (12/30 with 6 to 9 nt. deletions, 1/30
with a 10 nt. deletion). For both ATMi treated WT cells and
ATM
2/2 cells, we found an increase in the frequency of deletions
greater than 9 nt., as compared to DMSO treated WT cells (12/
30 for WT+ATMi, p=0.0011; 17/30 for ATM
2/2,p ,0.0001;
compared to 1/30 for WT). In contrast, for Nbs1
n/h cells we found
a reduction in clones showing deletions greater than 6 nt., in
comparison to WT cells (1/30 for Nbs1
n/h cells, p=0.0004;
compared to 13/30 for WT). In summary, while ATM and Nbs1
both suppress Distal End Utilization, these factors appear to show
divergent effects on end processing, with ATM suppressing longer
deletions, and Nbs1 promoting short deletions. Notably, for ATMi
treated Nbs1
n/h cells we found an increase in clones showing
deletions greater than 9 nts., as compared to either WT or Nbs1
n/h
cells (29/30 for Nbs1
n/h with ATMi, p,0.0001; compared to 1/30
for WT and 1/30 for Nbs1
n/h). This latter result indicates that the
increase in longer deletions caused by ATMi is dominant over the
decrease in short deletions caused by the Nbs1
n/h alleles.
The finding that Distal-EJ events in ATMi-treated cells show
longer deletions, yet are promoted by c-NHEJ factors, indicates
that deletion size may not necessarily be predictive of the
involvement of the c-NHEJ pathway. This result is consistent
with previous studies showing that while Xrcc4-deficiency causes
longer deletion EJ products, DNA-PKcs-deficiency does not lead
to elevated deletion sizes [38–41]. To confirm this distinction in
our experiments, we performed the above sequence analysis using
the DNA-PKcs
2/2 and Xrcc4
2/2 cell lines. Namely, we cloned
Distal-EJ amplification products from GFP+ sorted cells following
co-expression of I-SceI and Trex2 in these cell lines (p2, p3
products shown in Figure S1B), and subsequently sequenced 30
clones each (Figure 5, Table S1).
From this analysis, we found that junctions from DNA-PKcs
2/2
cells showed fewer deletions greater than 6 nts. in comparison to
WT cells (3/30 for DNA-PKcs
2/2, p=0.0074; compared to 13/30
for WT), along with a number of 1–5 nt. deletions (16/30). Thus,
DNA-PKcs
2/2 cells showed a shift towards shorter deletions as
compared to WT cells, similar to the findings of Nbs1
n/h cells. The
rest of the DNA-PKcs
2/2 junctions were +1 insertions (11/30),
which were not observed in WT cells, but were found in ATM
2/2
(9/30) and Nbs1
n/h cells (12/30). In contrast, Xrcc4
2/2 cells show
much more extensive deletions, with all clones showing $20 nt.
deletions (30/30), compared to none with WT cells (p,0.0001).
These results indicate that Xrcc4 is important to limit extensive
deletions during Distal-EJ, whereas DNA-PKcs promotes short
deletions.
Apart from variations in deletion size, use of microhomology
and templated nucleotides are distinct between individual repair
events, but these characteristics also are not necessarily predictive
Figure 4. Nbs1 suppresses Distal-EJ to a similar degree as ATM. A. Distal-EJ is elevated in Nbs1-deficient cells, and ATMi treatment shows a
diminished effect on Distal-EJ in these cells, compared to WT cells. Shown are the mean Distal-EJ frequencies for WT and Nbs1
n/h ES cells, each with an
integrated EJ5-GFP reporter, which were transfected and treated with DMSO or ATMi, as described in Figure 2 (N=6, error bars denote s.d.). (*)
statistical difference between DMSO versus ATMi treatments of the same cell line (p#0.0053), ({) statistical difference between WT and Nbs1
n/h cells
of the same treatment (p,0.0001). B. Proximal-EJ is not affected by Nbs1-deficiency. Shown are the mean frequencies of I-SceI-resistant p1, p2
amplification products (Proximal-EJ) for the transfection experiments described in A (N=6, error bars denote s.d.). (*) as in A, p,0.0001 for WT,
p=0.0156 for Nbs1
n/h. C. Distal End Utilization is elevated in Nbs1-deficient cells, and ATMi treatment shows a diminished effect on Distal End
Utilization in these cells, compared to WT cells. Shown are the mean Distal End Utilization values of individual samples relative to DMSO-treated WT
cells (N=6, error bars denote s.d.). (*) as in A (p#0.0011), ({)a si nA( p #0.0053).
doi:10.1371/journal.pgen.1001194.g004
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Xrcc4
2/2 cells showed any evidence of microhomology greater
than 4 nt. (19/30 show a junction with 6 nt. of microhomology).
The rest of the repair junctions observed in our experiments
showed 0–4 nt. of microhomology, without any clear distinction
between the cell lines. As the mechanistic requirements for limited
microhomology during different EJ pathways is still unclear
[42,43], EJ events with 0–4 nts. of microhomology could be
mediated by c-NHEJ factors or alt-EJ. Similarly, the +1 insertion
events likely involve Family X DNA Polymerases (Pol X), which
also could function during c-NHEJ or alt-EJ events [44]. Though,
in this case, we observe an increase in +1 insertion events in cells
deficient for Nbs1, ATM, and DNA-PKcs, which could reflect an
improved recruitment of Pol X polymerases during EJ.
To summarize the junction analysis, we found that ATM and
Xrcc4 limit the length of deletions, whereas Nbs1 and DNA-PKcs
promote short deletions. In contrast, we found that Distal-EJ is
suppressed via ATM and Nbs1, and that the elevated level of
Distal-EJ caused by ATM-disruption requires both Xrcc4 and
DNA-PKcs. These findings indicate that the role of individual
factors during end processing is not predictive of their role during
end utilization.
Discussion
Limiting the use of incorrect ends during EJ repair of multiple
chromosome breaks is likely an important aspect of genome
maintenance, and hence tumor suppression. Using a method for
quantifying end utilization during repair of two tandem DSBs, we
present evidence that ATM and Nbs1 are important to limit Distal
End Utilization. We also present evidence that the increase in
Distal-EJ that is caused by ATM-disruption is dependent on c-
NHEJ factors (DNA-PKcs, Xrcc4, and XLF). We suggest that
ATM and Nbs1 may suppress genome rearrangements not only
through activating the DDR, but also via promoting faithful end
utilization during c-NHEJ. This notion is consistent with
important previous studies showing that ATM supports correct
utilization of hairpin coding ends during V(D)J recombination via
c-NHEJ factors [13,16–20]. Our findings indicate that such a role
for ATM is not limited to Artemis-dependent c-NHEJ of hairpin
ends generated by the Rag1/2 endonuclease, but is also important
for Artemis-independent c-NHEJ repair of multiple DSBs with
open ends. In summary, we suggest that cells that are deficient in
ATM or Nbs1 are more prone to chromosome rearrangements
during c-NHEJ of multiple DSBs.
In addition, we find that c-NHEJ-deficiency does not cause a
substantial effect on Distal-EJ levels in ATM-proficient cells
(within 2-fold of WT, Figure 3A). This finding is consistent with
other studies showing that neither Ku70 nor Xrcc4 are required
for chromosomal translocations that result from repair of multiple
I-SceI-induced DSBs [45–48]. These studies have raised the
possibility that c-NHEJ factors may not play a role in promoting
chromosome rearrangements outside the programmed rearrange-
ments during lymphocyte development. Rather, these studies
suggested that alt-EJ mechanisms might be responsible for such
chromosome rearrangements. However, we have presented
evidence that c-NHEJ factors (Xrcc4, DNA-PKcs, and XLF) can
promote genome rearrangements caused by ATM-deficiency.
Thus, we suggest that c-NHEJ may indeed play a role during
genome rearrangements, but specifically under conditions that
enable incorrect end utilization (e.g. deficient in ATM or Nbs1).
Break persistence versus end tethering
The increase in Distal-EJ versus Proximal-EJ caused by
disruption of ATM (and/or Nbs1) could be due to at least two
mechanisms: increased break persistence and/or defective end
tethering (Figure 6). Considering the former, ATM-disruption
could enhance the persistence of each DSB, thereby increasing the
probability of both DSBs existing simultaneously, leading to more
Distal End Utilization. This model is supported by findings that
DSBs formed during V(D)J recombination in ATM-deficient cells
persist longer, even through multiple cell doublings [12–15].
However, c-NHEJ-deficiency also causes an increase in break
persistence [49], but does not lead to a substantial increase in
Distal-EJ. Thus, not all conditions that lead to elevated break
persistence appear to cause an increase in Distal-EJ. To
summarize the break persistence model, ATM (and/or Nbs1)
could be important to limit the persistence of DSBs, and thereby
reduce the probability that multiple DSBs occur simultaneously,
which would limit the frequency of chromosome rearrangements.
Alternatively, disruption of ATM and/or Nbs1 could cause
defective end tethering, thereby increasing the probability of distal
end synapsis, and hence Distal End Utilization. A role for Nbs1
during end synapsis is consistent with the DNA tethering activity
of the Mre11-complex (Mre11-Rad50-Nbs1) [50–52]. Such
tethering could be important not only for recruitment of the sister
chromatid during homologous recombination, but also for end
synapsis during EJ. ATM could support this tethering function of
the Mre11-complex, as Nbs1 is a target of ATM kinase activity
Figure 5. Discrete roles of individual factors on deletion size during Distal-EJ. ATM and Xrcc4 suppress longer deletions, whereas Nbs1 and
DNA-PKcs promote short deletions. Distal-EJ products were amplified and cloned for sequencing analysis from GFP+ sorted samples following co-




cells treated with ATMi, DNA-PKcs
2/2 cells, and Xrcc4
2/2 cells. Shown are the numbers of products (out of 30 total, sequences in Table S1) in five
different classifications: +1 insertion (ins.), 1 to 5 nt. deletions (del.), 6 to 9 nt. del., 10 to 19 nt. del., and $20 nt. del.
doi:10.1371/journal.pgen.1001194.g005
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number of factors to chromatin to activate the DDR, such factors
could stabilize damaged chromatin [53], and thereby support
faithful end tethering during repair. In a related model, ATM
could regulate the end tethering functions of c-NHEJ factors, since
ATM can phosphorylate XLF [54] and DNA-PKcs [55], the latter
of which can tether DNA molecules in vitro [56]. A role for ATM
during these events is supported by findings that combined loss of
ATM with DNA-PKcs or Lig4 caused substantially elevated levels of
broken mitotic chromosomes, as compared to either single mutant
[15,57]. Nbs1 could also be important for such ATM-dependent
mechanisms of end tethering, since Nbs1 activates ATM kinase
activity following DSBs [7]. Thus, ATM and/or Nbs1 could
support the end tethering functions of either the Mre11 complex
and/or c-NHEJ factors themselves, and thereby limit incorrect
end utilization during EJ.
Of course, these two aspects of repair need not be mutually
exclusive, as defects in end tethering could delay EJ causing
increased break persistence, and vice versa. However, we suggest
that even in situations of elevated DSB persistence, incorrect end
tethering is still essential for generation of Distal-EJ products. In
summary, we suggest that disruption of ATM (and/or Nbs1) leads
to defective end tethering and/or elevated break persistence in a
manner that results in a substantial elevation of incorrect end
utilization during c-NHEJ repair of multiple DSBs (Figure 6).
End utilization and end processing appear to be distinct
processes
We also find that individual factors show distinct effects on end
processing during EJ. The end processing observed in these
experiments could be influenced by 59 to 39 end resection, and/or
other mechanisms of DSB end degradation. Since Nbs1 appears to
promote 59 to 39 end resection during in vitro EJ assays [58], this
mechanism likely contributes to its role in promoting short
deletions during EJ.
In contrast to Nbs1, we find that ATM appears to suppress
deletions, which is supported by recent findings that ATM limits
terminal end processing of DNA ends in vitro, and during plasmid
EJ in vivo [59,60]. Furthermore, we find that ATMi causes longer
deletions even in the Nbs1-deficient cells. This result indicates that
loss of ATM-mediated end protection may enable the low level of
Nbs1 in these cells (5-fold reduced relative to WT [27]) to facilitate
end resection. Alternatively, loss of ATM-mediated end protection
could lead to an Nbs1-independent mechanism of end degrada-
tion. The former model is supported by a recent study showing
that Mre11 promotes the terminal end processing caused by
ATM-disruption [60]. Somewhat paradoxical to these findings of
ATM-mediated end protection, ATM has been shown to promote
end resection as measured by recruitment of ssDNA binding
protein (RPA) to DSBs [61], although apparently not in all
circumstances [62]. Perhaps ATM may limit terminal end
resection, but promote extensive end resection [61,63]. Such a
model is consistent with studies in yeast that support a two-step
end resection process [64].
Notably, ATM and Nbs1 affect end processing in different
directions, while both suppress Distal End Utilization. We also find
a distinction between Xrcc4 versus DNA-PKcs. Namely, we find
that Xrcc4 is important to limit the extent of deletions during EJ,
while DNA-PKcs promotes short deletions. This distinction is
consistent with other reports [38–41], as well as the notion that c-
NHEJ is a modular and flexible process that can result in a variety
of products [42]. In contrast, we find that both Xrcc4 and DNA-
PKcs are important for the elevated level of Distal-EJ caused by
ATM-disruption. In summary, these studies of ATM, Nbs1,
Xrcc4, and DNA-PKcs indicate that the regulation of end
processing appears to be distinct from that of end utilization.
Therapeutic relevance
In conclusion, correct end utilization is likely an important
mechanism for limiting chromosome rearrangements that can lead
to cancer development. While disruption of ATM kinase activity
may be beneficial for promoting tumor cell death via clastogenic
agents [31,65], such a therapeutic strategy may also disrupt
faithful end utilization in non-tumor cells, which could lead to
therapy-related malignancies. Conversely, developing therapeutic
strategies to enhance faithful end utilization in non-tumor cells
could have the potential to reduce therapy-related malignancies.
As well, since meganucleases are being developed as potential
genome engineering tools [66], we suggest that Trex2 expression
could enhance mutagenesis around the DSB site of meganucleases.
However, as such nucleases may form DSBs at multiple sites, we
also suggest that functional ATM would be critical for limiting





2/2 [32], and Artemis
2/2 [36] ES cells
were generously provided by Dr. Frederick Alt, and ATM
2/2 ES
cells [30] were generously provided by Dr. Yang Xu. Cells (10
7 in
0.8 ml Optimem, Invitrogen) were electroporated with 70mgo f
XhoI digested pim-EJ5-GFP at 710–720V/10mF. Hygromycin B




2/2 cells, as confirmed
by PCR analysis [28]. Puromycin selection (1.2 mg/ml) was used
to select random integrants of EJ5-GFP in ATM
2/2 cells.
Integration of an intact copy of the reporter in ATM
2/2 cells
was confirmed by Southern blot analysis, as described previously
[28]. Other cell lines with chromosomally integrated EJ5-GFP
were described previously: WT ES (AB2.2), Nbs1
n/h ES, Xrcc4
2/2
ES, and HEK293 [27,28].
Repair assays
Mouse ES and HEK293 cells were cultured as described
previously [28], and 10
5 cells were plated the day before an
incubation with a mixture of 0.8mg of pCBASce, 0.4mgo f
pCAGGS-Trex2, and 3.6mL of Lipofectamine 2000 (Invitrogen),
Figure 6. ATM limits incorrect end utilization during c-NHEJ of
two tandem DSBs. Shown is a diagram of EJ repair of two tandem
non-cohesive DSBs. Incorrect end utilization is shown to be caused by
elevated break persistence and/or incorrect end tethering. Notably,
even when individual breaks are more persistent, incorrect end
tethering is still essential to generate the Distal-EJ product. ATM/
Nbs1-deficiency is modeled to cause elevated break persistence and/or
incorrect end tethering, leading to incorrect end utilization during c-
NHEJ.
doi:10.1371/journal.pgen.1001194.g006
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media was removed and replaced with complete media containing
either 10mM ATMi [31](EMD Biosciences) or DMSO (vehicle).
Subsequently (3 days), half of each transfection sample was
analyzed by FACS (CyAN ADP, Dako) to determine %GFP+ cells
(Distal-EJ), and the other half was used to isolate genomic DNA
for determination of Proximal-EJ, as described previously [27].
Briefly, genomic DNA was amplified using EJ5purF (p1, 59
agcggatcgaaattgatgat) and KNDRR (p2, 59 aagtcgtgctgcttcatgtg).
The amplification products were purified (GFX, GE), and digested
with I-SceI (NEB), separated on agarose gels, and detected with
ethidium bromide, where complete digestion was confirmed with
parallel samples from untransfected cells. The percentage of I-
SceI-resistant product was calculated from the relative staining
intensity of I-SceI+ versus I-SceI-resistant bands within the same
lane, as described previously [27,29].
For single clone analysis, we performed the same transfection
protocol, except we included 0.4mg of dsRED-N1 (Clontech) and a
total of 4.8mL of Lipofectamine 2000. Three days after
transfection, we enriched for transfected cells by sorting dsRED+
cells, which we plated at low density to isolate single clones. For
each clone, we determined whether the 59 and 39 I-SceI sites had
been disrupted, using the Proximal-EJ assay described above,
where the 59 I-SceI site was analyzed using the primers KNDRF
(p3, 59 ctgctaaccatgttcatgcc) and EJ5purR (p4, 59 cttttgaagcgtgca-
gaatg) [27].
To calculate Distal End Utilization for individual samples, the
percentage of GFP+ cells was divided by the percentage of I-SceI-
resistant amplification products. To facilitate comparison to WT,
each individual Distal End Utilization value was divided by the
mean value for WT DMSO treated cells. We amplified Distal-EJ
products from GFP+ sorted cells from representative transfections,
using KNDRF (p3) and KNDRR (p2). The amplification products
were digested with I-SceI, as above. I-SceI-resistant bands were
isolated and cloned into TA vectors (Invitrogen) for sequencing
with the M13R primer.
Statistical analysis
For comparison of EJ frequencies, we used Student’s unpaired t-
test. For comparison of Distal-EJ breakpoint junctions, we used
Fisher’s Exact Test.
Supporting Information
Figure S1 Details of EJ assays. A. The Proximal-EJ assay is
quantitative within two-fold. WT mouse ES cells were transfected
with an expression vector for I-SceI (S), along with either the
Trex2 expression vector (S+Trex2), or empty vector (S+EV).
Following transfection, genomic DNA was isolated from S+Trex2
cells, and also from an equal mixture of S+Trex2 cells and S+EV
cells. As I-SceI-resistant Proximal-EJ products require Trex2
expression (see Figure 2B), the mixed sample should show a 2-fold
reduction in such products, as compared to the S+Trex2 sample.
Shown are representative Proximal-EJ products (left) along with
the mean Proximal-EJ value from separate transfections used to
generate independent samples (right, N=3, error bars denote s.d.).
(*) statistical difference between S+Trex2 versus the equal mixture
of S+EV and S+Trex2, p=0.0009. Also shown (left) are Proximal-
EJ products of an S+Trex2 transfection of Xrcc4
2/2 cells,
performed in parallel. B. Trex2 and I-SceI co-expression leads
to Distal-EJ products that are I-SceI-resistant. Several cell types







transfected as in A. Subsequently, GFP+ Distal-EJ products were
sorted and the restoration of the I-SceI site was determined by
PCR amplification and I-SceI digestion analysis as in Figure 2C.
Shown are uncut (U) and I-SceI-digested (S) products from these
samples. Some of these products were also shown in Figure 2C,
which we show here to enable comparison. C. Formation of I-
SceI-resistant Proximal-EJ products is dependent on Trex2
expression, including in ATM
2/2 cells. Shown are representative
Proximal-EJ samples from S+EV and S+Trex2 transfection of
ATM
2/2 cells, as described in A. D. ATMi treatment causes an
increase in Distal End Utilization when the end-point analysis is
performed at either 3 or 6 days. WT mouse ES cells were
transfected as in A, and cultured for 3 or 6 days prior to
determining Distal End Utilization values as described in
Figure 2D. Shown are the mean Distal End Utilization values
for independent transfections for 3 and 6 days end points (N$3,
error bars denote s.d.). (*) distinct from DMSO treatment from the
same end point, p,0.0014; values were not statistically different
between 3 and 6 days.
Found at: doi:10.1371/journal.pgen.1001194.s001 (0.81 MB
PDF)
Figure S2 Efficiency of I-SceI-induced DSBs at tandem
recognition sites; ATM limits Distal End Utilization in
HEK293 cells. A. ATM does not inhibit formation of I-SceI-
induced DSBs at both tandem I-SceI sites. WT mouse ES cells
were transfected with expression plasmids for I-SceI, Trex2, and
dsRED. Also, transfections were treated with DMSO or ATMi as
in Figure 2. Following transfection (3 days), dsRED+ cells were
sorted to enrich for transfected cells, and were plated at low
density to isolate single clones. Loss of the 59 and 39 I-SceI-
recognition sites was determined by PCR amplification and I-
SceI digestion for individual clones, using the primers depicted in
the diagram. Shown (left) are representative clones with loss of
both the 59 and 39 I-SceI sites (Clone 1), loss of only the 39 site
(Clone 2), and loss of only the 59 site (Clone 3). Also shown (right)
are the percentages of clones that have lost one I-SceI site (59 or
39 S - ,e . g .C l o n e s3o r2 ,r e s p e c t i v e l y )v e r s u sb o t hs i t e s( 5 9 and 39
S - ,e . g .C l o n e1 ) ,f o rD M S Oa n dA T M it r e a t e ds a m p l e s .B .A T M
suppresses incorrect end utilization in HEK293 cells. HEK293
cells with an integrated copy of EJ5-GFP were co-transfected
with expression plasmids for I-SceI and Trex2 and treated with
ATMi or DMSO. Shown are the mean frequencieso fD i s t a l - E J
(left), Proximal-EJ (middle), and Distal End Utilization (right) for
these samples, determinedasin Figure 2 (N=6, error bars denote
s.d.). (*) statistical difference between DMSO and ATMi
treatment (p,0.0001).
Found at: doi:10.1371/journal.pgen.1001194.s002 (0.35 MB
PDF)
Table S1 Sequences of Distal-EJ junctions. For reference, shown
is the unmodified I-SceI site in capital letters with the cleavage site
marked by a slash, which would be generated by Distal-EJ that
restores the I-SceI site. Shown are the five categories of products
shown in Figure 5, along with the sequences of each individual
repair product. Inserted nucleotides are in bold, substituted
nucleotides are in italics and bold, and microhomology is
underlined. Shown are the numbers of each product, out of 30
total, from analysis of Distal-EJ products (GFP+ cells), following
co-expression of I-SceI and Trex2, from a number of cell types: WT




n/h treated with ATMi, Xrcc4
2/2,a n dDNA-PKcs
2/2
(the p3, p2 I-SceI-resistant amplification products are shown in
Figure 2C, Figure S1B).
Found at: doi:10.1371/journal.pgen.1001194.s003 (0.08 MB
PDF)
ATM and End Utilization
PLoS Genetics | www.plosgenetics.org 9 November 2010 | Volume 6 | Issue 11 | e1001194Acknowledgments
We thank Corentin Laulier and Amanda Gunn for helpful discussions and
Anita Cheng for technical assistance.
Author Contributions
Conceived and designed the experiments: NB JMS. Performed the
experiments: NB JMS. Analyzed the data: NB JMS. Wrote the paper:
NB JMS.
References
1. Stephens PJ, McBride DJ, Lin M-L, Varela I, Pleasance ED, et al. (2009)
Complex landscapes of somatic rearrangement in human breast cancer
genomes. Nature 462: 1005–1010.
2. Lieber MR (2009) The Mechanism of Double-Strand DNA Break Repair by the
Nonhomologous DNA End-Joining Pathway. Annual Review of Biochemistry.
3. Haber JE (2008) Alternative endings. Proceedings of the National Academy of
Sciences 105: 405–406.
4. Shiloh Y (2003) ATM and related protein kinases: safeguarding genome
integrity. Nat Rev Cancer 3: 155–168.
5. Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432:
316–323.
6. Stracker TH, Theunissen JW, Morales M, Petrini JH (2004) The Mre11
complex and the metabolism of chromosome breaks: the importance of
communicating and holding things together. DNA Repair (Amst) 3: 845–854.
7. Difilippantonio S, Nussenzweig A (2007) The NBS1-ATM connection revisited.
Cell Cycle 6: 2366–2370.
8. van der Burgt I, Chrzanowska KH, Smeets D, Weemaes C (1996) Nijmegen
breakage syndrome. J Med Genet 33: 153–156.
9. Jankovic M, Nussenzweig A, Nussenzweig MC (2007) Antigen receptor
diversification and chromosome translocations. Nat Immunol 8: 801–808.
10. Shrivastav M, De Haro LP, Nickoloff JA (2008) Regulation of DNA double-
strand break repair pathway choice. Cell Res 18: 134–147.
11. Riballo E, Kuhne M, Rief N, Doherty A, Smith GCM, et al. (2004) A Pathway
of Double-Strand Break Rejoining Dependent upon ATM, Artemis, and
Proteins Locating to gamma-H2AX Foci. Mol Cell 16: 715–724.
12. Calle ´n E, Jankovic M, Difilippantonio S, Daniel JA, Chen H-T, et al. (2007)
ATM Prevents the Persistence and Propagation of Chromosome Breaks in
Lymphocytes. Cell 130: 63–75.
13. Bredemeyer AL, Sharma GG, Huang C-Y, Helmink BA, Walker LM, et al.
(2006) ATM stabilizes DNA double-strand-break complexes during V(D)J
recombination. Nature 442: 466–470.
14. Franco S, Gostissa M, Zha S, Lombard DB, Murphy MM, et al. (2006) H2AX
Prevents DNA Breaks from Progressing to Chromosome Breaks and
Translocations. Mol Cell 21: 201–214.
15. Calle ´n E, Jankovic M, Wong N, Zha S, Chen HT, et al. (2009) Essential role for
DNA-PKcs in DNA double-strand break repair and apoptosis in ATM-deficient
lymphocytes. Mol Cell 34: 285–297.
16. Deriano L, Stracker TH, Baker A, Petrini JHJ, Roth DB (2009) Roles for NBS1
in Alternative Nonhomologous End-Joining of V(D)J Recombination Interme-
diates. Mol Cell 34: 13–25.
17. Helmink BA, Bredemeyer AL, Lee B-S, Huang C-Y, Sharma GG, et al. (2009)
MRN complex function in the repair of chromosomal Rag-mediated DNA
double-strand breaks. The Journal of Experimental Medicine 206: 669–679.
18. Bredemeyer AL, Huang C-Y, Walker LM, Bassing CH, Sleckman BP (2008)
Aberrant V(D)J Recombination in Ataxia Telangiectasia Mutated-Deficient
Lymphocytes Is Dependent on Nonhomologous DNA End Joining. The Journal
of Immunology 181: 2620–2625.
19. Callen E, Bunting S, Huang CY, Difilippantonio MJ, Wong N, et al. (2009)
Chimeric IgH-TCRalpha/delta translocations in T lymphocytes mediated by
RAG. Cell Cycle 8: 2408–2412.
20. Zha S, Bassing CH, Sanda T, Brush JW, Patel H, et al. (2010) ATM-deficient
thymic lymphoma is associated with aberrant tcrd rearrangement and gene
amplification. The Journal of Experimental Medicine 207: 1369–1380.
21. Lumsden JM, McCarty T, Petiniot LK, Shen R, Barlow C, et al. (2004)
Immunoglobulin Class Switch Recombination Is Impaired in Atm-deficient
Mice. The Journal of Experimental Medicine 200: 1111–1121.
22. Kracker S, Bergmann Y, Demuth I, Frappart P-O, Hildebrand G, et al. (2005)
Nibrin functions in Ig class-switch recombination. Proceedings of the National
Academy of Sciences of the United States of America 102: 1584–1589.
23. Ramiro AR, Jankovic M, Callen E, Difilippantonio S, Chen H-T, et al. (2006)
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations.
Nature 440: 105–109.
24. Reina-San-Martin B, Chen HT, Nussenzweig A, Nussenzweig MC (2004) ATM
Is Required for Efficient Recombination between Immunoglobulin Switch
Regions. The Journal of Experimental Medicine 200: 1103–1110.
25. Reina-San-Martin B, Nussenzweig MC, Nussenzweig A, Difilippantonio S
(2005) Genomic instability, endoreduplication, and diminished Ig class-switch
recombination in B cells lacking Nbs1. Proceedings of the National Academy of
Sciences of the United States of America 102: 1590–1595.
26. Lee K, Zhang Y, Lee SE (2008) Saccharomyces cerevisiae ATM orthologue
suppresses break-induced chromosome translocations. Nature 454: 543–546.
27. Bennardo N, Gunn A, Cheng A, Hasty P, Stark JM (2009) Limiting the
Persistence of a Chromosome Break Diminishes Its Mutagenic Potential. PLoS
Genet 5: e1000683. doi:10.1371/journal.pgen.1000683.
28. Bennardo N, Cheng A, Huang N, Stark JM (2008) Alternative-NHEJ Is a
Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair.
PLoS Genet 4: e1000110. doi:10.1371/journal.pgen.1000110.
29. Weinstock DM, Nakanishi K, Helgadottir HR, Jasin M (2006) Assaying double-
strand break repair pathway choice in mammalian cells using a targeted
endonuclease or the RAG recombinase. Methods Enzymol 409: 524–540.
30. Xu Y, Baltimore D (1996) Dual roles of ATM in the cellular response to
radiation and in cell growth control. Genes & Development 10: 2401–2410.
31. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, et al. (2004)
Identification and Characterization of a Novel and Specific Inhibitor of the
Ataxia-Telangiectasia Mutated Kinase ATM. Cancer Research 64: 9152–9159.
32. Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, et al. (1998) A Targeted
DNA-PKcs-Null Mutation Reveals DNA-PK-Independent Functions for KU in
V(D)J Recombination. Immunity 9: 367–376.
33. Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, et al. (1998) A Critical Role for
DNA End-Joining Proteins in Both Lymphogenesis and Neurogenesis. Cell 95:
891–902.
34. Zha S, Alt FW, Cheng H-L, Brush JW, Li G (2007) Defective DNA repair and
increased genomic instability in Cernunnos-XLF-deficient murine ES cells.
Proceedings of the National Academy of Sciences 104: 4518–4523.
35. Tsai CJ, Kim SA, Chu G (2007) Cernunnos/XLF promotes the ligation of
mismatched and noncohesive DNA ends. Proceedings of the National Academy
of Sciences 104: 7851–7856.
36. Rooney S, Alt FW, Lombard D, Whitlow S, Eckersdorff M, et al. (2003)
Defective DNA Repair and Increased Genomic Instability in Artemis-deficient
Murine Cells. The Journal of Experimental Medicine 197: 553–565.
37. Yang Y-G, Saidi A, Frappart P-O, Min W, Barrucand C, et al. (2006)
Conditional deletion of Nbs1 in murine cells reveals its role in branching repair
pathways of DNA double-strand breaks. EMBO J 25: 5527–5538.
38. Liang F, Jasin M (1996) Ku80-deficient cells exhibit excess degradation of
extrachromosomal DNA. J Biol Chem 271: 14405–14411.
39. Schulte-Uentrop L, El-Awady RA, Schliecker L, Willers H, Dahm-Daphi J
(2008) Distinct roles of XRCC4 and Ku80 in non-homologous end-joining of
endonuclease- and ionizing radiation-induced DNA double-strand breaks.
Nucleic Acids Res 36: 2561–2569.
40. Guirouilh-Barbat J, Rass E, Plo I, Bertrand P, Lopez BS (2007) Defects in
XRCC4 and KU80 differentially affect the joining of distal nonhomologous
ends. Proceedings of the National Academy of Sciences 104: 20902–20907.
41. Fattah F, Lee EH, Weisensel N, Wang Y, Lichter N, et al. (2010) Ku regulates
the non-homologous end joining pathway choice of DNA double-strand break
repair in human somatic cells. PLoS Genet 6: e1000855. doi:10.1371/
journal.pgen.1000855.
42. Lieber MR (2010) The Mechanism of Double-Strand DNA Break Repair by the
Nonhomologous DNA End-Joining Pathway. Annual Review of Biochemistry
79.
43. McVey M, Lee SE (2008) MMEJ repair of double-strand breaks (director’s cut):
deleted sequences and alternative endings. Trends in Genetics 24: 529–538.
44. Moon AF, Garcia-Diaz M, Batra VK, Beard WA, Bebenek K, et al. (2007) The
X family portrait: structural insights into biological functions of X family
polymerases. DNA Repair (Amst) 6: 1709–1725.
45. Weinstock DM, Brunet E, Jasin M (2007) Formation of NHEJ-derived
reciprocal chromosomal translocations does not require Ku70. Nat Cell Biol
9: 978–981.
46. Weinstock DM, Richardson CA, Elliott B, Jasin M (2006) Modeling oncogenic
translocations: distinct roles for double-strand break repair pathways in
translocation formation in mammalian cells. DNA Repair (Amst) 5: 1065–1074.
47. Simsek D, Jasin M (2010) Alternative end-joining is suppressed by the canonical
NHEJ component Xrcc4-ligase IV during chromosomal translocation forma-
tion. Nat Struct Mol Biol 17: 410–416.
48. Guirouilh-Barbat J, Huck S, Bertrand P, Pirzio L, Desmaze C, et al. (2004)
Impact of the KU80 pathway on NHEJ-induced genome rearrangements in
mammalian cells. Mol Cell 14: 611–623.
49. Kuhne M, Riballo E, Rief N, Rothkamm K, Jeggo PA, et al. (2004) A Double-
Strand Break Repair Defect in ATM-Deficient Cells Contributes to Radiosen-
sitivity. Cancer Research 64: 500–508.
50. Moreno-Herrero F, de Jager M, Dekker NH, Kanaar R, Wyman C, et al. (2005)
Mesoscale conformational changes in the DNA-repair complex Rad50/Mre11/
Nbs1 upon binding DNA. Nature 437: 440–443.
51. Williams RS, Williams JS, Tainer JA (2007) Mre11-Rad50-Nbs1 is a keystone
complex connecting DNA repair machinery, double-strand break signaling, and
the chromatin template. Biochem Cell Biol 85: 509–520.
52. Wiltzius JJ, Hohl M, Fleming JC, Petrini JH (2005) The Rad50 hook domain is a
critical determinant of Mre11 complex functions. Nat Struct Mol Biol 12:
403–407.
ATM and End Utilization
PLoS Genetics | www.plosgenetics.org 10 November 2010 | Volume 6 | Issue 11 | e100119453. van Attikum H, Gasser SM (2009) Crosstalk between histone modifications
during the DNA damage response. Trends in Cell Biology 19: 207–217.
54. Yu Y, Mahaney BL, Yano K-I, Ye R, Fang S, et al. (2008) DNA-PK and ATM
phosphorylation sites in XLF/Cernunnos are not required for repair of DNA
double strand breaks. DNA Repair 7: 1680–1692.
55. Chen BPC, Uematsu N, Kobayashi J, Lerenthal Y, Krempler A, et al. (2007)
Ataxia Telangiectasia Mutated (ATM) Is Essential for DNA-PKcs Phosphory-
lations at the Thr-2609 Cluster upon DNA Double Strand Break. Journal of
Biological Chemistry 282: 6582–6587.
56. DeFazio LG, Stansel RM, Griffith JD, Chu G (2002) Synapsis of DNA ends by
DNA-dependent protein kinase. EMBO J 21: 3192–3200.
57. Sekiguchi J, Ferguson DO, Chen HT, Yang EM, Earle J, et al. (2001) Genetic
interactions between ATM and the nonhomologous end-joining factors in
genomic stability and development. Proc Natl Acad Sci U S A 98: 3243–3248.
58. Taylor EM, Cecillon SM, Bonis A, Chapman JR, Povirk LF, et al. (2010) The
Mre11/Rad50/Nbs1 complex functions in resection-based DNA end joining in
Xenopus laevis. Nucleic Acids Res 38: 441–454.
59. Rahal EA, Henricksen LA, Li Y, Turchi JJ, Pawelczak KS, et al. (2008) ATM
mediates repression of DNA end-degradation in an ATP-dependent manner.
DNA Repair (Amst) 7: 464–475.
60. Rahal EA, Henricksen LA, Li Y, Williams RS, Tainer JA, et al. (2010) ATM
regulates Mre11-dependent DNA end-degradation and microhomology-medi-
ated end joining. Cell Cycle 9.
61. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, et al. (2006) ATM- and cell
cycle-dependent regulation of ATR in response to DNA double-strand breaks.
Nat Cell Biol 8: 37–45.
62. Yuan J, Chen J (2010) MRE11-RAD50-NBS1 complex dictates DNA repair
independent of H2AX. J Biol Chem 285: 1097–1104.
63. Bothmer A, Robbiani DF, Feldhahn N, Gazumyan A, Nussenzweig A, et al.
(2010) 53BP1 regulates DNA resection and the choice between classical and
alternative end joining during class switch recombination. J Exp Med 207:
855–865.
64. Mimitou EP, Symington LS (2009) DNA end resection: many nucleases make
light work. DNA Repair (Amst) 8: 983–995.
65. Bolderson E, Richard DJ, Zhou BB, Khanna KK (2009) Recent advances in
cancer therapy targeting proteins involved in DNA double-strand break repair.
Clin Cancer Res 15: 6314–6320.
66. Paques F, Duchateau P (2007) Meganucleases and DNA double-strand break-
induced recombination: perspectives for gene therapy. Curr Gene Ther 7:
49–66.
ATM and End Utilization
PLoS Genetics | www.plosgenetics.org 11 November 2010 | Volume 6 | Issue 11 | e1001194